FDA Accepts NDA for Vonoprazan (Voquenza) in Non-Erosive GERD

The NDA submission was supported by positive data from the phase 3 PHALCON-NERD-301 study and has been assigned a standard 10-month review with a PDUFA target action date of July 19, 2024.

Related Keywords

,Azmi Nabulsi ,Drug Administration ,Phathom Pharmaceuticals Announces Positive Topline ,Phathom Pharmaceuticals ,Phathom Pharmaceuticals Announces ,Phathom Pharmaceuticals Announces Vonoprazan ,Phathom Pharmaceutical ,Prescription Drug User Fee Act ,New Drug Application ,Tablets New Drug Application ,Heartburn Associated ,Evaluating Daily Dosing ,Gerd ,Non Erosive Gerd ,Gastroesophageal Reflux Disease ,Phalcon Nerd 301 ,Heartburn ,Phase 3 ,Study ,Trial ,Vonoprazan ,Voquenza ,